ERBB2 and neoplasm: T‐DXd, also an anti‐HER2 targeted agent, utilizes a topoisomerase I inhibitor payload with a cleavable linker, enabling higher drug‐to‐antibody ratios and bystander effects that allows activity also in HER2‐low tumours.